C12Y 207/01022
Ribosylnicotinamide kinase
Official title: Ribosylnicotinamide kinase (2.7.1.22)
C12Y207/01022 (Ribosylnicotinamide kinase) appears on 2 US grants and 4 published applications in this corpus.
Search patents in C12Y- Granted patents
- 2
- Published applications
- 4
- Assignees
- 4
- Inventors
- 14
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2021 | 0 | 1 |
| 2022 | 0 | 2 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor25 Aug 2026US 12,714,722 B2Fred Hutchinson Cancer Center
- 4-thioribose NAD analogues and methods of synthesizing and using the same5 Dec 2023US 11,834,470 B2University of Southern California
- Enzyme composition for preparing beta-nicotinamide mononucleotide, and application thereof22 Aug 2024US 2024/0279699 A1Shenzhen Readline Biotech Co., Ltd.
- 4-thioribose nad analogues and methods of synthesizing and using the same21 Jul 2022US 2022/0227803 A1University of Southern California
- Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor28 Apr 2022US 2022/0125814 A1Fred Hutchinson Cancer Research Center
- Biosynthesis of preparing nicotinamide mononucleotide and derivatives thereof12 Aug 2021US 2021/0246476 A1
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.